Penumbra Secures CE Mark for THUNDERBOLT, Expanding Stroke Treatment Tech to Europe
Event summary
- Penumbra received CE Mark approval for THUNDERBOLT, its Computer Assisted Vacuum Thrombectomy (CAVT) technology, on June 15, 2026.
- The technology introduces modulated aspiration for acute ischemic stroke, enabling faster and more complete clot removal.
- THUNDERBOLT is the only CAVT device available for stroke treatment in both Europe and the U.S.
- Penumbra received U.S. FDA clearance for THUNDERBOLT the previous week.
The big picture
Penumbra's expansion into Europe with THUNDERBOLT underscores the growing demand for advanced stroke treatment technologies amid rising global stroke mortality rates. The company's unique position as the sole provider of CAVT technology across both vascular and neurovascular care positions it to transform clot treatment from head-to-toe. The strategic move comes as stroke mortality is projected to increase by 50% between 2020 and 2050, highlighting the critical need for innovative solutions in this space.
What we're watching
- Market Penetration
- How quickly Penumbra can integrate THUNDERBOLT into European stroke treatment protocols and capture market share.
- Regulatory Dynamics
- Whether the pending acquisition by Boston Scientific Corporation will impact Penumbra's ability to focus on THUNDERBOLT's global rollout.
- Competitive Response
- The pace at which competitors develop similar CAVT technologies to challenge Penumbra's dominance in the neurovascular field.